MCT2D Clinician Decision Aid: SGLT-2 Inhibitor / GLP-1 RA for Type 2 Diabetes


Updated: 10/16/23

SGLT2 inhibitors and GLP-1 receptor agonists are first-line treatments for T2D in patients with cardiorenal disease. This aid is meant to be used alongside your own clinical judgment, guideline-directed therapy, and prescribing information to guide individualization of diabetes treatment.
Lead clinical author is Heidi Diez, PharmD, clinical pharmacist, with Michael Heung, MD, nephrologist.

Tags: For Providers, Point-of-care, Created By MCT2D

MCT2D Newsletter

Subscribe to the MCT2D Newsletter

Once per month we deliver news, updates, events, and more directly to you!